Meetings

  • Enabling Rapid Response and Sustained Capability with Medical Countermeasures to Mitigate Risk of Emerging Infectious Diseases: An Institute of Medicine Workshop Date: March 26, 2015 - March 27, 2015 (8:30 AM Eastern)

    This workshop, hosted by the Forum on Medical and Public Health Preparedness for Catastrophic Events, the Forum on Drug Discovery, Development, and Translation, and the Forum on Microbial Threats will bring together public and private stakeholders to discuss how to achieve rapid and nimble medical countermeasure development for new and emerging threats. Discussions will include real-world case studies to elucidate how past events were handled from a policy, budget, and operational standpoint, and contribute to a better aggregate picture of how future “worst case scenarios” might unfold. This workshop will examine principles that either enable or challenge strong public/private partnerships and consider the needs of the private sector to successfully ramp up research, development, and production in a rapid and nimble manner once a threat warrants the need.
  • Financial Incentives to Support Unmet Medical Needs for Nervous System Disorders: A Workshop Date: January 20, 2015 - January 21, 2015 (8:30 AM Eastern)

    This workshop will explore opportunities to foster private sector innovation by supporting new investments directed toward the development of novel therapeutics to meet unmet needs for nervous system disorders.
  • Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products Date: May 12, 2014 (9:00 AM Eastern)

    This two-part public workshop series will address the opportunity to advance the development of more systematic and structured approaches to characterize and communicate (a) the sources of uncertainty in the assessment of benefits and risks; and (b) their implications for pharmaceutical regulatory decisions. Specifically, the workshop series will explore potential analytical and communication approaches and identify key considerations on their development, evaluation, and incorporation into the assessment of benefits and risks in pharmaceuticals.
  • Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products Date: February 12, 2014 - February 13, 2014 (9:00 AM Eastern)

    Discuss the challenges in applying more systematic approaches to characterizing and communicating uncertainty in the assessment of a drug’s benefits and risks.
  • International Regulatory Harmonization Amid Globalization of Biomedical Research & Medical Product Development Date: February 13, 2013 - February 14, 2013 (8:30 AM Eastern)

    This public workshop will address needs for international harmonization of regulatory standards to support the development, evaluation and surveillance of biomedical products. Specifically, the discussions at the workshop will help identify principles, potential approaches, and strategies to advance the development or evolution of more harmonized regulatory standards.
  • The Global Crisis of Drug-Resistant Tuberculosis and the Leadership of the BRICS Countries: Challenges and Opportunities Date: January 16, 2013 - January 18, 2013 (7:00 AM Eastern)

    The increasing burden of drug-resistant tuberculosis introduces new challenges to traditional TB control and treatment programs and calls upon the global health community to collaborate and share scientific information in new and different ways. This 3-day workshop is sponsored by the Forum on Drug Discovery, Development, and Translation of the U.S. National Academy of Sciences, Institute of Medicine (IOM) and the Institute of Microbiology of the Chinese Academy of Sciences (CAS). Following an inaugural meeting in Washington, D.C. in 2008, this workshop in Beijing is the fourth in a series of international workshops convened by the U.S. IOM. The objective of the workshop series is to realistically assess the impact of and challenges resulting from drug-resistant TB globally and in the four countries with the most people affected (China, India, Russia, and South Africa).
  • Large Simple Trials and Knowledge Generation in a Learning Health System Date: November 26, 2012 - November 27, 2012 (1:00 PM Eastern)

    The workshop will explore the opportunities and challenges associated with leveraging the rapid digitalization of health care to accelerate the use of large simple trials (LSTs), and the speed and practicality of knowledge generation for medical decision making and medical product development in a continuously learning health system.
  • IOM Workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB Date: July 31, 2012 - August 1, 2012 (8:00 AM Eastern)

    Two-day workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB.
  • Maximizing the Goals of the Cures Acceleration Network to Accelerate the Development of New Drugs and Diagnostics: A Workshop Date: June 4, 2012 - June 5, 2012 (8:30 AM Eastern)

    This public workshop will consider options and opportunities to maximize the usefulness and impact of the CAN program in order to advance translational sciences. In addition to providing suggestions to NCATS, the workshop is, in part, in response to Congressional interest in CAN expressed in the FY 2012 appropriations act conference report.
  • Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020 Date: November 7, 2011 - November 8, 2011 (8:30 AM Eastern)

    The Institute of Medicine will conduct a workshop that will explore issues related to Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020. More specifically, the workshop will: (1) frame the problem and discuss a vision for a clinical trials enterprise that is efficient and effective and fully integrated into the health delivery system of 2020; (2) define how the envisioned clinical trials enterprise differs from the current system and suggest approaches to transform our current system into a learning system; and (3) consider core themes in framing an agenda to effect transformation of the U.S. clinical trials enterprise, including the development of a robust clinical trials workforce, the alignment of cultural and financial incentives, and building an infrastructure to support a transformed clinical trials enterprise.